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Abstract
Background: Disrupting the balance of histone lysine methylation alters the expression of genes
involved in tumorigenesis including proto-oncogenes and cell cycle regulators. Methylation of lysine
residues is commonly catalyzed by a family of proteins that contain the SET domain. Here, we
report the identification and characterization of the SET domain-containing protein, Smyd2.
Results: Smyd2 mRNA is most highly expressed in heart and brain tissue, as demonstrated by
northern analysis and in situ hybridization. Over-expressed Smyd2 localizes to the cytoplasm and
the nucleus in 293T cells. Although accumulating evidence suggests that methylation of histone 3,
lysine 36 (H3K36) is associated with actively transcribed genes, we show that the SET domain of
Smyd2 mediates H3K36 dimethylation and that Smyd2 represses transcription from an SV40-
luciferase reporter. Smyd2 associates specifically with the Sin3A histone deacetylase complex,
which was recently linked to H3K36 methylation within the coding regions of active genes in yeast.
Finally, we report that exogenous expression of Smyd2 suppresses cell proliferation.
Conclusion: We propose that Sin3A-mediated deacetylation within the coding regions of active
genes is directly linked to the histone methyltransferase activity of Smyd2. Moreover, Smyd2
appears to restrain cell proliferation, likely through direct modulation of chromatin structure.
Background
Cell proliferation and differentiation are coordinated by
synchronized patterns of gene expression. The regulation
of these patterns is achieved, in part, through epigenetic
mechanisms that affect the nature of DNA packaging into
chromatin [1]. Specifically, post-translational covalent
modifications to histone tails impact the structural
dynamics of the nucleosome, thereby affecting DNA
accessibility to transcriptional complexes [2-4]. Common
modifications to histones include methylation, acetyla-
tion, phosphorylation, and ubiquitination [5]. Impor-
tantly, alterations in global levels of histone methylation
and acetylation are connected to the biology of cancerous
lesions and their clinical outcome [6]. A number of his-
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Alignment of the mammalian Smyd family proteins, and Smyd2 localization Figure 1
Alignment of the mammalian Smyd family proteins, and Smyd2 localization. (A) Schematic representation of the 
five mammalian Smyd proteins. The split SET domain is shown in light gray; the MYND domain is represented in black and the 
cysteine-rich post-SET domain is displayed in dark gray. Positions of the amino acids are indicated. (B) Expression of Smyd1, 
Smyd2, and Smyd3 transcripts in tissues. Top panel: Smyd3 mRNA is most highly expressed in the thymus and in skeletal mus-
cle [8]. Middle panel: Smyd2 mRNA is most highly expressed in the heart and brain. Bottom panel: Smyd1 expression is 
restricted to the heart and skeletal muscle [20]. Transcripts for Smyd1, Smyd2, and Smyd3 are expressed in the embryo. (C) 
ClustalW alignment of the amino-terminal SET residues, the MYND domain, and the core SET residues followed by the post-
SET domain present in Smyd1, Smyd2, Smyd3, Smyd4, and Smyd5. (D) Smyd2 is localized to the cytoplasm and the nucleus. 
Exponentially growing 293T cells were transfected with 1 μg of plasmids, encoding myc tagged Smyd2. 48 hr post-transfection, 
cells were fixed, washed, permeabilized and exposed to monoclonal mouse anti-myc antibody. Nuclei were counterstained 
with DAPI. Right panel: Smyd2 (red) localizes to both the nucleus and the cytoplasm of 293T cells. Left panel: Nuclei were 
counterstained with DAPI (blue). The experiments were repeated in triplicate with identical results. (E) Smyd2 mRNA is local-
ized in the heart and hypothalamus of the brain at E13.5. Whole-mount in situ hybridization of Smyd2 transcripts in embryos at 
day 13.5 post coitus were prepared by exposition of sense (right panel) and antisense (middle panel) DNA probes, specific to 
Smyd2 to the sections. Whereas hybridization with sense probe resulted in no signal (right panel), thus, serving as control, 
Smyd2 mRNA is easily detected in the heart and the hypothalamus of the brain in embryos at day 13.5 post coitus (middle 
panel).
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tone lysine methyltransferases (HKMTs) are disrupted in
a variety of cancer types [7,8]. How histone methylation
mechanistically contributes to the oncogenic state is
poorly understood.
All known HKMTs, with one exception [5], catalyze
methyl transfer via the SET domain, a module encoded
within many proteins that regulate diverse processes,
including those critical for development and proper pro-
gression of the cell cycle [2,9,10]. Histone lysine methyla-
tion on specific residues typically correlates with distinct
states of gene expression [5]. Histone 3 (H3) contains
most of the known targeted lysines of histone methyl-
transferases and thereby serves as a conduit of such epige-
netic regulation. In general, lysine methylation on H3K9,
H3K27, and H4K20 corresponds with gene silencing,
whereas methylation of H3K4, H3K36, or H3K79 is asso-
ciated with actively transcribed genes [5]. Methylation of
H3K36 (H3K36me) is tightly associated with actively
transcribed genes [11,12], and appears to correspond pri-
marily within the coding region. H3K36 methylation by
Set2 in yeast was recently observed to recruit an Rpd3-
mediated histone deacetylase complex through direct rec-
ognition of H3K36me by the chromodomain of Eaf3 [13-
15]. Rpd3 is a histone deacetylase (HDAC) that has well-
established functions as a transcriptional repressor [13].
Rpd3 associates into several co-repressor complexes,
including one that contains Pho23, Sds3, Sap30, Ume1,
Cti6/Rxt1, and Sin3 [13]. However, recent evidence sug-
gests that HDACs may also play a role during active tran-
scription. As such, methylation of H3K36 is directly
linked to histone deacetylation via Rpd3-Sin3 that in turn
functions to maintain chromatin structure during active
transcription [13-15]. These findings reveal a new level of
complexity with respect to histone modifications, and
demonstrate our need to better understand the enzymes
that catalyze these modifications.
Here we describe a subfamily of SET domain containing
proteins with a unique domain architecture. This family
of proteins is defined by a SET domain that is split into
two segments by an MYND domain, followed by a
cysteine-rich post SET domain [16] (Fig. 1A). Members of
this family may be important developmental regulators,
as targeted disruption of the Smyd1 gene results in
impaired cardiomyocyte maturation, flawed cardiac mor-
phogenesis, and embryonic lethality [17]. Functionally,
Smyd1 is thought to regulate gene expression via its asso-
ciation with histone deacetylase activity [17]. Smyd3 has
been noted for its involvement in cancer cell proliferation
[8]. It is over-expressed in most hepatocellular and color-
ectal carcinomas, and its exogenous over-expression in
NIH3T3 cells significantly augmented growth [8,18,19].
Similar to Smyd1, Smyd3 modulates chromatin structure
through its intrinsic H3K4-specific HKMT activity [8].
Although Smyd2 is highly conserved with Smyd1 and
Smyd3, nothing is known about its biochemical or func-
tional activities. Here, we demonstrate that Smyd2 con-
tains SET-domain dependent H3K36 HKMT activity.
Smyd2 specifically associates with the Sin3A histone
deacetylase complex, suggesting a link between two inde-
pendent chromatin modification activities. Moreover, we
observe that over-expression of Smyd2 in NIH3T3 cells
significantly suppresses their growth. We propose that
Smyd2-mediated chromatin modification regulates spe-
cific gene expression that has important implications for
normal and neoplastic cell proliferation.
Results
Structural characteristics and expression of Smyd2
Although there are over 50 SET domain-containing pro-
teins encoded in the human genome, only a fraction have
been shown to methylate histones. Of all the SET pro-
teins, five cluster into a sub-family that contains a SET
domain that is split into two segments by a MYND
domain/zinc-finger motif, implicated previously in pro-
tein-protein interactions (SET and MYND)(Fig. 1C).
Members of this family are direct regulators of cancer
(Smyd3) and essential developmental processes (Smyd1)
[8,17]. Thus, it is important to discern the biochemical
and biological properties of Smyd2, given its high degree
of homology to Smyd1 and Smyd3. Data from Expressed
Sequence Tags suggest that Smyd2 is expressed in a wide
range of normal, tumor, and diseased tissues (data not
shown). To determine the tissues of highest gene expres-
sion, northern blotting was performed with a multiple tis-
sue blot using a probes specific to Smyd1, Smyd2, or
Smyd3. The northern analyses (Fig. 1B) demonstrate that
in contrast to Smyd1, Smyd2 and Smyd3 mRNAs are
expressed more broadly in a wide variety of tissues.
Smyd1 is expressed only in T lymphocytes, heart muscle,
and skeletal muscle, as previously reported [20]. Smyd3
expression is highest in skeletal muscle [8] and thymus
(Fig. 1B), although its transcripts are also highly detected
in the brain, kidney, and ovary (Fig. 1B). Tissues contain-
ing highest levels of Smyd2 mRNA transcripts include
heart, brain, liver, kidney, thymus, and ovary (Fig. 1B.)
Additionally, both Smyd2 and Smyd3 transcripts are
detectable in embryonic mRNA, suggesting that as with
Smyd1, Smyd2 and Smyd3 may be involved in develop-
ment (Fig. 1B). To determine which embryonic tissues
manifest highest levels of Smyd2 transcripts, whole-
mount in situ hybridization was performed using murine
embryos at day 13.5 with a probe specific to Smyd2. At
this mid-gestation stage, Smyd2 transcripts are localized
to the heart and the hypothalamus of the brain (Fig. 1E).
Immunohistochemical staining of Smyd1 and Smyd3
indicated that both proteins localize within the cytoplasm
and nucleus of C2C12 [21] and Huh7 cells [8], respec-Molecular Cancer 2006, 5:26 http://www.molecular-cancer.com/content/5/1/26
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Smyd2 dimethylates Histone H3 lysine 36 Figure 2
Smyd2 dimethylates Histone H3 lysine 36. (A) Smyd2 methylates histone H3 in an in vitro histone methyl transferase 
(HKMT) assay using mixed histones from calf thymus as substrate. Fluorograms are shown in the upper panel; the 17 kD band, 
corresponding with Histone H3, is indicated; Coomassie stained SDS-PAGE gels were used to verify equal loading and are 
depicted in the lower panels. Lanes 1 and 3 show positive HKMT activity at H3 by myc tagged Smyd3 and myc tagged Smyd2, 
respectively. Lanes 2 and 4 indicate that neither the Smyd3 (Y239F) nor the Smyd2 (Y240F) catalytic mutants have HKMT 
activity. It is concluded that the HKMT activity of Smyd3 depends on Y239 and Y240 for Smyd2. (B) Smyd2 methylates Histone 
H3 in an in vitro histone methyl transferase assay using recombinant octamers as substrate. Fluorograms are shown in the 
upper panel; the 17 kD band, corresponding with Histone H3, is indicated; Coomassie stained SDS-PAGE gels were used to 
verify equal loading and are depicted in the lower panels. Histone H3 was found methylated by Smyd2 using recombinant 
octamers as substrate in an in-vitro HKMT assay. (C) Smyd2 methylates histone H3 in an in vitro histone methyl transferase 
assay using recombinant histone H3 as a substrate. Fluorograms are shown in the upper panel; the 17 kD band, corresponding 
with histone H3, is indicated; Coomassie stained SDS-PAGE gels were used to verify equal loading and are depicted in the 
lower panels. Histone H3 was found methylated by Smyd2 using recombinant octamers as substrate in an in-vitro HKMT assay 
(lane 1). The catalytically defective mutant Smyd2 (Y240F) failed to methylate recombinant histone H3 (lane 2). It is concluded 
that the HKMT activity of Smyd2 depends on Y240. (D) Smyd2 does not dimethylate histone H3 at lysine 4 using recombinant 
histone H3 as a substrate in an in-vitro HKMT assay. Western results, using antibodies, specifically reactive with dimethylated 
histone H3, lysine 4, are shown; the 17 kD band, corresponding with histone H3, is indicated. Lanes 1 and 4 indicate that 
immunoprecipitated and myc-tagged Smyd3, but not myc-tagged Smyd2, dimethylates histone H3 at lysine 4. Lanes 2 and 5 
show that neither Smyd2 (Y240F) nor Smyd3 (Y239F) dimethylate histone H3 at lysine 4. We conclude that Smyd2 does not 
dimethylate histone H3 at lysine 4. (E) Smyd2 dimethylates histone H3 lysine 36 using recombinant histone H3 as a substrate in 
an in-vitro HKMT assay. Western results, using antibodies, specifically reactive with dimethylated histone H3, lysine 36, are 
shown; the 17 kD band, corresponding with histone H3, is indicated. Lanes 1 and 3 indicate that Smyd2 dimethylates recom-
binant histone H3 at lysine 36, independent of the myc or Gal4 tag. The catalytically inactive mutant Y240F does not dimethyl-
ate recombinant histone H3 at lysine 36 (lane 2). Smyd3, as well as the catalytically defective mutant Y239F, do not dimethylate 
recombinant histone H3 at lysine 36 (lanes 4 and 5). We conclude that Smyd2 dimethylates recombinant histone H3 at lysine 
36, whereas Smyd3 does not display this activity.
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Smyd2 associates with the Sin3 repression complex and is involved in transcriptional repression Figure 3
Smyd2 associates with the Sin3 repression complex and is involved in transcriptional repression. (A) Expression 
of GAL4-Smyd2 fusion protein in 293T cells. Exponentially grown 293T cells were transfected with the constructs indicated 
and, 48 hours post transfection, whole cell lysate was prepared using RIPA buffer and subjected to western analysis using anti-
bodies directed against the GAL4 tag. A reactive band was detected at the appropriate molecular weight (approximately 66 
kD). Extracts from cells, transfected with the GAL4-DBD construct [17], served as negative control. (B) Smyd2 represses tran-
scription of a luciferase reporter. Top panel: Schematic illustration of the reporter construct used. Bottom panel: 10T1/2 cells 
were transiently co-transfected with the 5XGAL4-SV40-luciferase reporter (1 μg) together with GAL4-DBD or GAL4-Smyd2 
(2 μg each). Percent activity of the luciferase was determined in relation to GAL4-DBD. Smyd2 significantly represses the tran-
scription of a luciferase reporter in 10T1/2 cells. (C) Smyd2 associates with HDAC1. Exponentially grown 293T cells were 
transiently co-transfected with GAL4-DBD or GAL4-Smyd2, together with Flag tagged HDAC1 (HDAC1-F). Whole cell RIPA 
extracts were immunoprecipitated using an anti-GAL4 antibody and immunoblots were probed with an anti-FLAG antibody. 
As shown here, Smyd2 associates with HDAC1. RIPA whole cell extracts from GAL4-DBD transfected cells [17] served as 
negative control. Equal protein amounts in the immunopreciptation assays was demonstrated by analysis of 5% input using anti 
Flag antibodies. (D) Smyd2 interacts with the Sin3A but not the NuRD complex. Exponentially grown 293T cells were trans-
fected with the constructs indicated and, 48 hours post transfection, whole RIPA lysate was prepared. Antibodies directed 
against GAL4 were used for immunoprecipitation, followed by western analysis using the antibodies indicated. Smyd2 associ-
ates with HDAC1 and Sin3A but not with the components of the NuRD complex, MBD3 or MTA2.Molecular Cancer 2006, 5:26 http://www.molecular-cancer.com/content/5/1/26
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tively. To determine the subcellular localization of
Smyd2, immunohistochemical staining was performed
using a myc-tagged Smyd2 fusion protein. Similar to
Smyd1 and Smyd3, Smyd2 localizes within both the cyto-
plasm and the nucleus (Fig. 1D).
Smyd2 is a SET-dependent HKMT
Smyd2 contains the catalytic core residues of the SET
domain shown to be critical for the histone methyltrans-
ferase activity of Smyd1 and Smyd3 (Fig. 1C) [22,8]. This
suggests that Smyd2 may also possess HKMT activity. His-
tone methylation was tested after incubation of wild-type
Smyd2-Myc (or Smyd3-Myc as a positive control) with S-
adenosyl-L – [methyl-3H ] methionine (SAM) and mixed
histones from calf thymus as a substrate. A 17 kD band
corresponding to 3H-labelled H3 was seen with both
Smyd3 and Smyd2 in the fluorogram (Fig. 2A, lanes 1 and
3), indicating that Smyd2 has intrinsic HKMT activity. A
tyrosine in the C-terminal region of the core SET domain
is conserved among catalytically active SET domain pro-
teins (Fig. 1C). Therefore, to test if the SET domain is
required for the HKMT activity observed for Smyd2, point
mutations were made in this residue of Smyd3-Myc
(Y239F) and Smyd2-Myc (Y240F). Neither Smyd3
(Y239F)-Myc nor Smyd2 (Y240F)-Myc displayed HKMT
activity (Fig. 2A, lanes 2 and 4).
Smyd2 HKMT activity was next tested on a recombinant
histone H3 substrate. Wild-type Smyd2-Myc methylated
H3 (Fig. 2C, lane 1) but Smyd2 (Y240F)-Myc showed no
HKMT activity (Fig. 2C, lane 2). To test the activity of
untagged Smyd2 protein, Smyd2 was expressed as a GST
fusion in E. coli and the GST moiety was subsequently
cleaved. Methylation of recombinant histone octamers
was tested after incubation with recombinant Smyd2.
Consistently, recombinant Smyd2 was observed to meth-
ylate histone H3 (Fig. 2B, lane 1). Therefore, we conclude
that the Smyd2 has SET domain-dependent, intrinsic
HKMT activity.
Smyd2 dimethylates H3K36
Given that both Smyd1 and Smyd3 have been shown to
have specificity for H3K4 [22,8], we tested whether
Smyd2 has similar specificity. Histone methyltransferase
assays were performed using recombinant H3, and specif-
icity was determined by western blotting using antibodies
against various methyl-lysine residues. The antibodies
used in these assays include anti-dimethyl H3K4, anti-tri-
methyl H3K4, anti-dimethyl H3K9, anti-trimethyl H3K9,
anti-trimethyl H3K27, anti-di-methyl H3K36, and anti-
dimethyl H3K79. A 17 KD band corresponding to H3 was
observed with Smyd3, but not with Smyd2, when reac-
tions were probed with anti-dimethyl H3K4 (Fig. 2D,
lanes 4 and 1, respectively) or anti-trimethyl H3K4 (data
not shown). This indicated that Smyd2 has a different tar-
get specificity than Smyd1 or Smyd3. Instead, the HKMT
activity of Smyd2 was specific for H3K36, as determined
by western blotting with anti-dimethyl H3-K36 antibod-
ies (Fig. 2E, lanes 1 and 3). No additional residues
appeared to be targeted by Smyd2 using the other anti-
bodies listed above (data not shown). Therefore, we con-
clude that Smyd2 dimethylates H3K36.
Smyd2 associates with HDAC1 and the Sin3 repression 
complex
Smyd3 induces transcriptional activation by binding to
specific promoter sequences [8]. In contrast, Smyd1 is
known to repress transcription when fused to GAL4 by
association with HDAC activity [17]. Given that Smyd2
has activity towards H3K36, a mark associated with active
transcription, we tested the transcriptional regulatory
activity of Smyd2. A GAL4-fusion protein was generated
using Smyd2 and transient luciferase assays were per-
formed in 10T1/2 cells. Unexpectedly, Smyd2-GAL4
inhibited transcription from an SV40 promoter that con-
tained GAL4 binding sites (Fig. 3B), suggesting it may
function similarly to Smyd1.
Although methylation of H3K36 is associated with
actively transcribed genes, three recent reports have dem-
onstrated that in yeast, methylation of H3K36 by Set2
recruits an Rpd3-Sin3 histone deacetylase complex
[13,14]. Our finding that Smyd2 contains H3K36 methyl-
ation activity and functions to repress transcription in the
above assay prompted us to investigate whether Smyd2
interacts with the human homologues of the Rpd3-Sin3
complexes. In transient transfection experiments in 293T
cells, the human homologue of Rpd3, HDAC1, interacted
specifically with Smyd2-GAL4 upon immunoprecipita-
tion with anti-GAL4 antibodies (Fig. 3C). Consistently,
when cell extracts from 293T cells over-expressing Smyd2-
GAL4 were immunoprecipitated with anti-GAL4 anti-
body, the immune complexes contained endogenous
Sin3A (Fig. 3D). In contrast, Smyd2-GAL4 failed to coim-
munoprecipitate FLAG-tagged MBD3 and MTA2, compo-
nents of the HDAC1-containing NuRD complex (Fig. 3D).
Thus, we conclude that Smyd2 preferentially interacts
with distinct HDAC1-containing complexes, namely
Sin3A.
Smyd2 suppresses cell proliferation
The role of Smyd3 in transcriptional regulation as a his-
tone methyltransferase has been linked to its ability to
augment cellular proliferation [8]. To investigate the
effects that Smyd2 may have on cell proliferation,
NIH3T3 cells were transfected with either Smyd2-Myc or
Smyd3-Myc. Relative to control and consistent with previ-
ous findings [8], over-expression of Smyd3 markedly
increased cell growth (Fig. 4). Conversely, the transfection
of 3T3 cells with Smyd2 led to a decrease in their prolifer-Molecular Cancer 2006, 5:26 http://www.molecular-cancer.com/content/5/1/26
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ation (Fig. 4), indicating a potential role for Smyd2 in the
maintenance of cell-cycle progression.
Discussion
Great strides have been made in the interpretation of cov-
alent histone modifications regarding their role in tran-
scriptional regulation. Histone lysine methylation has
been found to affect the structure of chromatin thereby
establishing complex patterns of gene expression [23]. In
some cases, these patterns are clearly defined. For exam-
ple, H3K4 methylation is most often associated with the
establishment of euchromatin and the consequent activa-
tion of local gene expression [3]. Reciprocally, methyla-
tion at H3K9 is commonly involved with the formation of
heterochromatin and the ensuing silencing of nearby gene
transcription [3,4].
Initial data on the yeast HKMT, Set2, indicated that it
functions in transcriptional repression by methylating
H3K36 [24]. However, the HKMT activity of Set2 was later
linked to the elongation phase of RNA polymerase II
(RNAPII) [25,26]. Likewise, in a more contemporary
study, an analysis of the distribution of H3K36 methyla-
tion in metazoans correlated this modification with
actively transcribed genes [11]. Most recently, methyla-
tion of H3K36 by Set2 has been associated with the
recruitment of a histone deacetylase complex, Rpd3 [13].
The overall role and implications of histone deacetylation
within the coding regions of active genes is still unknown.
In mammalian epigenetics, NSD1 was one of the first
HKMTs reported to act on H3K36 [27]. Whether NSD1
functions in the activation or repression of transcription
Smyd2 suppresses NIH3T3 cell proliferation Figure 4
Smyd2 suppresses NIH3T3 cell proliferation. Exponentially grown NIH3T3 cells were transfected with plasmids encod-
ing myc-tagged Smyd2 or myc-tagged Smyd3. Cells, transfected with the empty expression construct (Mock), served as con-
trol. All cells were monitored by cell counting using trypan blue exclusion. The inserts show the level of expression of Smyd2-
myc and Smyd3-myc at 0 and 144 hours post transfection, demonstrating similar levels of ectopically introduced proteins in the 
NIH3T3 cell lines used. Whereas ectopically introduced Smyd3 enhanced the proliferation, Smyd2 displayed a negative effect 
on the growth rate of NIH3T3 cells.Molecular Cancer 2006, 5:26 http://www.molecular-cancer.com/content/5/1/26
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has yet to be determined. A recent investigation reported
that the human HYPB protein methylates H3K36 and that
this enzymatic activity is required for the role of HYPB as
a transcriptional activator [28].
Our findings introduce Smyd2 as an H3K36-specific
HKMT that acts as a transcriptional repressor. Clearly,
there are other transcriptional regulatory mechanisms at
work in conjunction with the methylation of H3K36. It
seems that the more we learn about where histone marks
are localized and what proteins facilitate the process, the
less we are certain about how such localization ultimately
contributes to gene regulation. Although this complicates
our ability to apply a broad interpretation of histone
modifications, it provides a clear direction for the pursuit
of a deeper fold in the "histone code."
Smyd2 regulatory functions
Transcriptional assays demonstrated that Smyd2 can
repress transcription from a luciferase reporter gene (Fig.
3B). A recent study in yeast demonstrated that methyla-
tion of H3K36 recruits a histone deacetylase complex,
Rpd3 [13]. Concurrently, another group concluded that
H3K36 methylation-induced recruitment of an Rpd3
complex resulted in the reversal of lysine acetylation
related to the elongation phase of RNAPII, suggesting that
it functioned to stem intragenic transcription initiation
[14]. This is reminiscent of the mechanism by which the
FACT complex functions. That is, as the elongation com-
plex traverses a coding region, FACT facilitates both desta-
bilization of the chromatin structure, to impart efficient
and processive elongation, as well as reorganization of the
chromatin to prevent intragenic initiation of transcription
[29]. Whereas H3K36 methylation recruits the Rpd3 com-
plex, it has been suggested that FACT recruitment may
occur through its association with CHD1, which recog-
nizes trimethylated H3K4 [30]. As the Rpd3 complex is
known to contain Sin3 [13], it was particularly informa-
tive to find that Smyd2 also associates with Sin3. It will be
of further interest to determine whether in vivo recruit-
ment of Sin3 requires H3K36 methylation, the presence of
Smyd2, or both.
Over-expression of Smyd2 in NIH3T3 cells significantly
reduces cell growth. In a previous study, cell proliferation
assays demonstrated that Smyd3 augmented cell growth
when introduced into NIH3T3 cells [8]. It is well estab-
lished that cell proliferation and differentiation are coor-
dinated by synchronized patterns of gene transcription. In
the case of Smyd3, enhancement of cell growth has been
shown to be dependent upon the H3K4-specific HKMT
activity of the Smyd3 protein [8]. It will be informative to
determine whether the suppressive effect of Smyd2 on cell
growth requires its function as an H3K36-specific HKMT.
Such a determination, in tandem with identification of
putative gene target specificity of Smyd2 will provide a
broader mechanistic model of how the Smyd family may
function.
Histone lysine methylation is more stable than other
known post-translational modifications, persisting as
long as several rounds of cell division [31-33]. This makes
lysine methylation potentially valuable in diverse, long-
lasting signaling networks, not only in the nucleus for his-
tone and non-histone proteins, such as p53 and TAF10,
but conceivably in the cytoplasm. The findings that
Smyd1 and Smyd3 can localize in the cytoplasm [21,8]
along with our observation that Smyd2 is also capable of
cytosolic localization, lends credence to this idea. This
argument is further strengthened by the finding that
Smyd1 moves from the nucleus to the cytoplasm during
myogenic differentiation [21]. Another SET domain-con-
taining HKMT, Ezh2 and its partners Eed and Suz12,
reside primarily in the cytoplasm of various mouse and
human cells [34,35]. Within the nucleus, the Ezh2 com-
plex catalyzes H3K27 methylation, whereas the cytosolic
Ezh2 binds Vav1, a controller of Rho family GTPases, and
Ezh2 is important for signaling events previously attrib-
uted to Vav1 [34-36]. There is no evidence that Ezh2
methylates Vav1, so the significance of lysine methylation
in the cytoplasm remains unclear. However, we are cur-
rently testing the role of Smyd2-mediated lysine methyla-
tion in the formation of stable and potentially heritable
cytosolic signaling complexes with Smyd2 interaction
partners and we plan to track these complexes, once
formed, within resting and dividing cells.
The Smyd family
The Smyd HKMTs are set apart from other such chromatin
modifying enzymes by the split nature of their SET
domains. The SET domain of each Smyd protein is
divided by a MYND domain (Figure 1A &1C), a zinc-fin-
ger motif that mediates protein-protein interactions. This
domain is found in several transcriptional regulators
shown to mediate distinct biological functions [37,38].
For example, the MYND domain of Smyd1 is essential for
its interaction with the muscle-specific transcription fac-
tor, skNAC [21]. Additionally, ETO, a common target of
chromosomal translocations in acute myeloid leukemia,
directs transcriptional repression through an intact
MYND domain [39]. Thus, the importance of the MYND
domain in gene regulation has been well established and
it may provide some insight into other mechanisms at
work through Smyd2 that affect the overall outcome of its
activity in transcriptional regulation. The complete func-
tion of Smyd2 in vivo is likely dependent upon other pro-
teins and complexes, in addition to HDAC1 and Sin3A,
with which it associates. We are currently screening several
other candidate interaction partners whose nature mayMolecular Cancer 2006, 5:26 http://www.molecular-cancer.com/content/5/1/26
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give further clues to mechanisms and pathways regulated
by Smyd2.
Northern blot analysis revealed that Smyd2 and Smyd3
are expressed in a wide variety of tissues (Fig. 1B) whereas
Smyd1 is more restricted in its tissue distribution [20].
Studies of ours and others on Smyds1-3 suggest that Smyd
family members function through a common mecha-
nism, specifically, lysine methylation. It is reasonable to
assume that individual Smyd proteins associate with dif-
ferent transcription factors and other effector proteins that
ultimately dictate specific gene regulation. No other Smyd
family member is functionally redundant with Smyd1,
since homozygous Smyd1-null mice are embryonic lethal
at day E10.0 as a result of impaired cardiomyocyte differ-
entiation [17]. The significant expression of Smyd2 in the
in embryonic heart (Fig. 1B, E) suggests that as with
Smyd1, Smyd2 may regulate cardiac development. The
identification of the biological functions of Smyd family
proteins will undoubtedly reveal new insights into the
relationships between chromatin modifications and the
development and differentiation of specific tissues.
Conclusion
We conclude that Smyd2 dimethylates H3K36 and that
HDAC1-mediated deacetylation of the coding regions of
active genes is directly linked to this histone methyltrans-
ferase activity of Smyd2. We further propose that this role
of Smyd2 in the regulation of gene expression ultimately
restrains cell proliferation. As it is clear from this study,
future research on Smyd proteins, with strong emphasis
on the unique organismal context, will shed light onto the
biological functions of Smyd family proteins, revealing
new and fascinating insights into the relationships
between chromatin modifications and the development
and differentiation of tissues and organisms.
Methods
Computational analysis
The Smyd family members were identified from BLAST
comparisons using the protein databases found at the
National Center for Biotechnology Information (NCBI)
web site http://www.ncbi.nlm.nih.gov/. The ClustalW
and BOXSHADE programs were used for alignments and
shading of Smyd family proteins
Cell culture
Cells lines were grown in DMEM, supplemented with
10% fetal bovine serum, 1 mM L-glutamine, 1% non-
essential amino acids, penicillin, streptomycin, and fung-
izone (all from Life Technologies), at 37°C in a humidi-
fied atmosphere of 5% CO2. We used 293T, 10T1/2 and
NIH3T3 cells, obtained from ATCC, in this study.
Constructs
The SV40-luciferase reporter, containing five copies of the
GAL4-UAS, was obtained from J. Milbrandt [25]. pRL-TK
was purchased from Promega. The GAL4-mammalian
expression construct, GAL4-DBD (DNA-binding
domain), has been described previously [17]. The Smyd2
and Smyd3 full-length EST clones were obtained from
Invitrogen. The GAL4-Smyd2 mammalian expression vec-
tor was constructed by PCR amplification (5' ATG CGC
GCC GAG GCC CGC; 3' TCA GTG GCT CTC AAT CTC
CTG) and restriction digestion (Not I; Xba I) followed by
subcloning into the GAL4-DBD plasmid [17]. The Myc-
Y240F and Myc-Y239F point mutations were generated
within the SET domain of Myc-Smyd2 (5' CGA GGT GTT
CAC CAG CTT CAT CGA CCT GCT ATA TCC; 3' GGA TAT
AGC AGG TCG ATG AAG CTG GTG AAC ACC TCG) and
Myc-Smyd3 (5' GGA GCT CAC CAT CTG CTT CCT GGA
CAT GCT GAT GAC C; 3' GGT CAT CAG CAT GTC CAG
GAA GCA GAT GGT GAG CTC C), respectively, using the
GeneEditor  in vitro Site-Directed Mutagenesis System
(Promega) according to the instructions of the manufac-
turer. The FLAG-tagged HDAC1-F mammalian expression
plasmid was a kind gift from S.L. Schreiber [40]. GST-
fusion proteins were prepared in E. coli and purified using
glutathione agarose beads (Sigma-Aldrich). GST- cleavage
was accomplished using PreScission Protease (Amersham
bioscience); purity of the products was verified using sil-
ver staining of SDS-PAGE gels. The FLAG-tagged MBD3-F
and MTA2-F expression plasmids were supplied by R.M.
Evans [41]. The sequences of all constructs were con-
firmed by DNA sequencing.
Transient transfections and luciferase assays
All transfections were performed using FuGENE6 reagent
(Roche), according to the instructions of the manufac-
turer. For immunoprecipitation experiments, 293T cells
were plated at a density of 2 × 106 cells per 100 mm plate
24 hours prior to transfection. 8 μg of total DNA plus 24
μl of FuGENE6 reagent was used per 100 mm plate. Cells
were harvested 48 hours after transfection. For luciferase
reporter assays, 10T1/2 cells were seeded at a density of 2
× 105 cells per 6-well plate 24 hours prior to transfection.
3.5 μg of total DNA plus 10.5 μl of FuGENE6 reagent was
used per well. Luciferase assays were performed using the
Dual-Luciferase Reporter Assay System kit (Promega)
according to the manufacturer's directions. Samples were
read using a Dynex microtiter luminometer.
Antibodies
The anti-Myc mouse monoclonal (9E10) and monoclonal
anti-FLAG (M2) antibodies were purchased from Sigma-
Aldrich. The anti-GAL4 mouse monoclonal (RK5C1) and
the anti-Sin3A rabbit polyclonal (K-20) antibodies were
purchased from Santa Cruz Biotechnology. Antibodies for
determining the specificity of HKMT activity are detailedMolecular Cancer 2006, 5:26 http://www.molecular-cancer.com/content/5/1/26
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below. Peroxidase-conjugated whole IgG secondary anti-
bodies were purchased from Jackson ImmunoResearch
Laboratories. Western blotting and immunoprecipitation
experiments were conducted as described previously [21].
Multiple tissue northern analysis
Northern blotting was performed using ULTRAhyb
Hybridization Buffer (Ambion) according to the instruc-
tions of the manufacturer. The probes for full-length
Smyd2 and Smyd3 were generated by restriction digest
excision (Not I; Xba I) from their respective GAL4 mam-
malian expression constructs and the Strip-EZ DNA Probe
Synthesis Kit (Ambion) as described in the manual. The
probe for full length Smyd1 was generated by restriction
digest excision (EcoRI) from the pBK-CMV-Smyd1B
expression construct described previously [21]. The multi-
ple tissue Northern blot was purchased from Ambion
(FirstChoice Northern Blot Mouse Blot I). Blots were
detected using a phosphoimager.
In situ hybridization
The DNA probe for full-length Smyd2 was generated by
restriction digest excision (Not I; Xba I) from its above
described GAL4 mammalian expression construct. Probe
synthesis, hybridization, and autoradiography were per-
formed as described in Lu et al. [42] with slight modifica-
tions. Briefly, embryos were obtained at day 13.5 post
coitus and fixed overnight in 4% paraformaldehyde.
Hybridization of tissue sections with sense and antisense
DNA probes was performed overnight at 55°C, 7.5 × 105
cpm per slide. Unhybridized probe was removed through
stringent washing and slides were coated with K.5 nuclear
emulsion (Ilford, UK) followed by exposure at 4°C for 21
days. Once developed, slides were counterstained with
hematoxylin and observed by bright and dark field optics.
Cellular localization by fluorescence imaging
293T cells were transfected with 1 μg of plasmids, encod-
ing myc tagged Smyd2, using Fugene 6 (Roche), according
to the manufacturer's instructions. 48 hr post-transfec-
tion, cells were fixed (4% paraformaldehyde in PBS for 10
min), washed, and permeabilized (0.5% Triton X-100 in
PBS for 15 min). Monoclonal mouse anti-myc antibody
was incubated 45 min at room temperature. After wash-
ing, goat anti-mouse Alexa 488 (Molecular Probes) was
diluted 1:400 in 2% BSA and incubated 15 min at room
temperature in the dark. Nuclei were counterstained with
DAPI. Slides were washed twice for 45 min and mounted
with VectaStain. Cells were analyzed by sequential confo-
cal laser scanning microscopy (Leica SP2 AOBS).
Cell proliferation assay
NIH3T3 cells were transfected with 6 μg of Smyd2-Myc,
Smyd3-Myc or pcDNA3 alone. The effect of the over-
expression of each protein on cell growth was observed
over a 6-day period and evaluated by cell counting using
trypan-blue staining.
In vitro histone methyltransferase assay
293T cells were transfected with plasmids expressing Myc-
tagged wildtype Smyd2 (Smyd2-Myc), wildtype Smyd3
(Smyd3-Myc), mutant Smyd2 (Smyd2 (Y240F)-Myc), or
mutant Smyd3 (Smyd3 (Y239F)-Myc) and the over-
expressed, tagged proteins were purified by immunopre-
cipitation with an anti-Myc antibody. The histone methyl-
transferase assay was performed as described in
Hammamoto et al. [8]. Briefly, the Smyd proteins were
incubated with 1 μg of mixed histones from calf thymus
(Sigma) or recombinant H3 (Upstate). In addition, 2 μCi
S-adenosyl-L – [methyl-3H ] methionine (SAM; Amer-
sham Biosciences) was included as a methyl donor. All
reactions were carried out in 40 μl HKMT reaction buffer
(10 mM dithiothreitol, 100 mM NaCl, and 50 mM Tris-
HCl at pH 8.8) at 30°C for 3 hours. An 18% SDS-PAGE
gel was used to resolve the samples and fluorography was
used visualize positive methylation. Substrate loading was
visualized by Coomassie blue staining.
To determine the specificity of Smyd2 activity, immuno-
precipitated Smyd proteins were incubated with recom-
binant H3 and 20 μM unlabelled SAM (Sigma) in 40 μl
HKMT reaction buffer at 30°C for 1 hour. Western blot
analysis was conducted using antibodies against dimeth-
ylated H3K4, trimethylated H3K4, dimethyl H3K9, trime-
thyl H3K9, trimethyl H3K27, dimethyl H3K36, or
dimethyl H3K79 (all from Upstate, Charlottesville, VA,
USA).
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
All authors participated in the design of experiments.
M.A.B. was responsible for northern analyses, cell locali-
zation studies, histone methyltransferase assays, and cell
proliferation assays. M.A.B. and R.J.S. performed all west-
ern blots and prepared all of the novel constructs. R.J.S.
was responsible for protein interaction data, luciferase
assays, protein alignments, and critical examination of the
manuscript. P.D.G. and P.W.T. coordinated and acquired
funding for the study. P.W.T. revised the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
The authors thank June Harriss and Jason Wall for expert technical assist-
ance. We are grateful to Tara Rasmussen for the restriction digest excision 
of Smyd2 probe for the in situ hybridization and to Ryan Sze for his assist-
ance in the creation of point mutations within the SET domains of Smyd2-
Myc and Smyd3-Myc. We thank Drs. James Richardson and Deepak Srivas-
tava for help with the whole-mount in situ hybridization and Li Zhu for dis-Molecular Cancer 2006, 5:26 http://www.molecular-cancer.com/content/5/1/26
Page 11 of 11
(page number not for citation purposes)
cussions and insights. This work was supported by the Marie Betzner 
Morrow Endowment to P.W.T. and by grants NIH grants (AI47209 and 
HL071160) to P.D.G., D.S., and P.W.T.
References
1. Sims RJ 3rd, Reinberg D: From chromatin to cancer: a new his-
tone lysine methyltransferase enters the mix.  Nat Cell Biol
2004, 6:685-687.
2. Jenuwein T, Allis CD: Translating the histone code.  Science 2001,
293:1074-1080.
3. Boggs BA, Cheung P, Heard E, Spector DL, Chinault AC, Allis CD:
Differentially methylated forms of histone H3 show unique
association patterns with inactive human X chromosomes.
Nat Genet 2002, 30:73-76.
4. Peters AH, Mermoud JE, O'Carroll D, Pagani M, Schweizer D, Brock-
dorff N, Jenuwein T: Histone H3 lysine 9 methylation is an epi-
genetic imprint of facultative heterochromatin.  Nat Genet
2002, 30:77-80.
5. Sims RJ 3rd, Nishioka K, Reinberg D: Histone lysine methylation:
a signature for chromatin function.  Trends Genet 2003,
19:629-639.
6. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani
SK: Global histone modification patterns predict risk of pros-
tate cancer recurrence.  Nature 2005, 435:1262-1266.
7. Ayton PM, Cleary ML: Molecular mechanisms of leukemogene-
sis mediated by MLL fusion proteins.  Oncogene 2001,
20:5695-5707.
8. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu
R, Nakamura Y: SMYD3 encodes a histone methyltransferase
involved in the proliferation of cancer cells.  Nat Cell Biol 2004,
6:731-740.
9. Kouzarides T: Histone methylation in transcriptional control.
Curr Opin Genet Dev 2002, 12:198-209.
10. O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA, Jenuwein T:
The polycomb-group gene Ezh2 is required for early mouse
development.  Mol Cell Biol 2001, 21:4330-4336.
11. Bannister AJ, Schneider R, Myers FA, Thorne AW, Crane-Robinson
C, Kouzarides T: Spatial distribution of di- and tri-methyl
lysine 36 of histone H3 at active genes.  J Biol Chem 2005,
280:17732-17736.
12. Rao B, Shibata Y, Strahl BD, Lieb JD: Dimethylation of histone H3
at lysine 36 demarcates regulatory and nonregulatory chro-
matin genome-wide.  Mol Cell Biol 2005, 25:9447-9459.
13. Keogh MC, Kurdistani SK, Morris SA, Ahn SH, Podolny V, Collins SR,
Schuldiner M, Chin K, Punna T, Thompson NJ, Boone C, Emili A,
Weissman JS, Hughes TR, Strahl BD, Grunstein M, Greenblatt JF,
Buratowski S, Krogan NJ: Cotranscriptional set2 methylation of
histone H3 lysine 36 recruits a repressive Rpd3 complex.  Cell
2005, 123:593-605.
14. Carrozza MJ, Li B, Florens L, Suganuma T, Swanson SK, Lee KK, Shia
WJ, Anderson S, Yates J, Washburn MP, Workman JL: Histone H3
methylation by Set2 directs deacetylation of coding regions
by Rpd3S to suppress spurious intragenic transcription.  Cell
2005, 123:581-592.
15. Joshi AA, Struhl K: Eaf3 chromodomain interaction with meth-
ylated H3-K36 links histone deacetylation to Pol II elonga-
tion.  Mol Cell 2005, 20:971-978.
16. Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M,
Opravil S, Mechtler K, Ponting CP, Allis CD, Jenuwein T: Regulation
of chromatin structure by site-specific histone H3 methyl-
transferases.  Nature 2000, 406:593-599.
17. Gottlieb PD, Pierce SA, Sims RJ, Yamagishi H, Weihe EK, Harriss JV,
Maika SD, Kuziel WA, King HL, Olson EN, Srivastava D: Bop
encodes a muscle-restricted protein containing MYND and
SET domains and is essential for cardiac differentiation and
morphogenesis.  Nat Genet 2002, 31:25-32.
18. Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, Nakamura Y:
Molecular diagnosis of colorectal tumors by expression pro-
files of 50 genes expressed differentially in adenomas and
carcinomas.  Oncogene 2002, 21:4120-4128.
19. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsu-
noda T, Furukawa Y, Nakamura Y: Genome-wide analysis of gene
expression in human hepatocellular carcinomas using cDNA
microarray: identification of genes involved in viral carcino-
genesis and tumor progression.  Cancer Res 2001, 61:2129-2137.
20. Hwang I, Gottlieb PD: The Bop gene adjacent to the mouse
CD8b gene encodes distinct zinc-finger proteins expressed
in CTLs and in muscle.  J Immunol 1997, 158:1165-1174.
21. Sims RJ, Weihe EK, Zhu L, O'Malley S, Harriss JV, Gottlieb PD: m-
Bop, a repressor protein essential for cardiogenesis, inter-
acts with skNAC, a heart- and muscle-specific transcription
factor.  J Biol Chem 2002, 277:26524-26529.
22. Tan X, Rotllant J, Li H, Deyne PD, Du SJ: SmyD1, a histone meth-
yltransferase, is required for myofibril organization and mus-
cle contraction in zebrafish embryos.  Proc Natl Acad Sci USA
2005, 103:2713-2718.
23. Cyrus M, Zhang Y: The diverse functions of histone lysine
methylation.  Nat Rev Mol Cell Biol 2005, 6:838-849.
24. Strahl BD, Grant PA, Briggs SD, Sun ZW, Bone JR, Caldwell JA, Mollah
S, Cook RG, Shabanowitz J, Hunt DF, Allis CD: Set2 is a nucleo-
somal histone H3-selective methyltransferase that mediates
transcriptional repression.  Mol Cell Biol 2002, 22:1298-1306.
25. Gerber M, Shilatifard A: Transcriptional elongation by RNA
polymerase II and histone methylation.  J Biol Chem 2003,
278:26303-26306.
26. Li J, Moazed D, Gygi SP: Association of the histone methyltrans-
ferase Set2 with RNA polymerase II plays a role in transcrip-
tion elongation.  J Biol Chem 2002, 277:49383-49388.
27. Rayasam GV, Wendling O, Angrand PO, Mark M, Niederreither K,
Song L, Lerouge T, Hager GL, Chambon P, Losson R: NSD1 is
essential for early post-implantation development and has a
catalytically active SET domain.  EMBO J 2003, 22:3153-3163.
28. Sun XJ, Wei J, Wu XY, Hu M, Wang L, Wang HH, Zhang QH, Chen
SJ, Huang QH, Chen Z: Identification and characterization of a
novel human histone H3 lysine 36-specific methyltrans-
ferase.  J Biol Chem 2005, 280:35261-35271.
29. Belotserkovskaya R, Reinberg D: Facts about FACT and tran-
script elongation through chromatin.  Curr Opin Genet Dev 2004,
14:139-146.
30. Reinberg D, Sims RJ 3rd: de FACTo Nucleosome Dynamics.  J
Biol Chem 2006. doi/10.1074/jbc.R600007200.
31. Byvoet P, Shepherd G, Hardin J, Noland B: The distribution and
turnover of labeled methyl groups in histone fractions of cul-
tured mammalian cells.  Arch Biochem Biophys 1972, 148:558-567.
32. Martin C, Zhang Y: The diverse functions of histone lysine
methylation.  Nat Rev Mol Cell Biol 2005, 6:838-849.
33. Cheung P, Lau P: Epigenetic regulation by histone methylation
and histone variants.  Mol Endocrinol 2005, 19:563-573.
34. Su I, Dobenecker M, Dickinson E, Oser M, Basavaraj A, Marqueron R,
Viale A, Reinberg D, Wulfing C, Tarakhovsky A: Polycomb group
protein ezh2 controls actin polymerization and cell signal-
ing.  Cell 2005, 121:425-436.
35. Nolz J, Gomez T, Billadeau D: The Ezh2 methyltransferase com-
plex: actin up in the cytosol.  Trends Cell Biol 2005, 10:514-517.
36. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P,
Jones R, Zhang Y: Role of histone H3 lysine 27 methylation in
Polycomb-group silencing.  Science 2002, 298:1039-1043.
37. Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S,
Lasher R, Trujillo J, Rowley J, Drabkin H: Identification of break-
points in t(8;21) acute myelogenous leukemia and isolation
of a fusion transcript, AML1/ETO, with similarity to Dro-
sophila segmentation gene, runt.  Blood 1992, 80:1825-1831.
38. Veraksa A, Kennison J, McGinnis W: DEAF-1 function is essential
for the early embryonic development of Drosophila.  Genesis
2002, 33:67-76.
39. Zhang X, Tamaru H, Khan SI, Horton JR, Keefe LJ, Selker EU, Cheng
X: Structure of the Neurospora SET domain protein DIM-5,
a histone H3 lysine methyltransferase.  Cell 2002, 111:117-127.
40. Grozinger CM, Hassig CA, Schreiber SL: Three proteins define a
class of human histone deacetylases related to yeast Hda1p.
Proc Natl Acad Sci USA 1999, 96:4868-4873.
41. Shago M, Giguere V: Isolation of a novel retinoic acid-respon-
sive gene by selection of genomic fragments derived from
CpG-island-enriched DNA.  Mol Cell Biol 1996, 16:4337-4348.
42. Lu J, Richardson JA, Olson EN: Capsulin: a novel bHLH tran-
scription factor expressed in epicardial progenitors and mes-
enchyme of visceral organs.  Mech Dev 1998, 73:23-32.